It Was a Bad Year for Stocks, and a Worse Year for Tesla
By BY JACK EWING from NYT Business https://ift.tt/XuPqRVM
Popular posts from this blog
The Patients Who Don't Want to Be Cured
Jeff Johnson is 40 years old, and for all 40 of those years, he has been living with hemophilia. The genetic disorder prevents blood from properly clotting, which, if untreated, can cause uncontrollable bleeding. Yet, Johnson says, he does not want a cure. He grew up with hemophilia, went to summer camp with kids with hemophilia, and forged some of his closest relationships within the community. I was interested in speaking to Johnson because new advances in gene therapy and gene editing are making the elusive cure seem closer than ever. At least five clinical trials are currently aiming to fix the faulty genes that underlie hemophilia. The New York Times recently interviewed patients from one gene-therapy trial who no longer had to worry about bruising and bleeding. “They Thought Hemophilia Was a ‘Lifelong Thing,’” read the headline. “They May Be Wrong.” It is unknown how long the effects of the therapy will last. “I’ve been told the hemophilia cure is around the corner for
'We've always said it's uphill': Quotes from Day 8 of Trump's Senate impeachment trial
A Democratic push for witnesses at Donald Trump's U.S. Senate impeachment trial appeared to flag on Wednesday, raising the possibility the president could be acquitted as early as Friday, as the White House objected to the publication of a book by former national security adviser John Bolton. from Reuters: U.S. https://ift.tt/37Dy2St
Comments
Post a Comment